| Ident. | Authors (with country if any) | Title |
|---|
| 000A15 |
Manel Sabate [Espagne] ; Salvatore Brugaletta [Espagne] ; Alexandre Abizaid [Brésil] ; Adrian Banning [Royaume-Uni] ; Antonio Bartorelli [Italie] ; Vladimír Dzavik [Canada] ; Stephen Ellis [États-Unis] ; David Holmes [États-Unis] ; RUNLIN GAO [République populaire de Chine] ; MYUNG HO JEONG [Corée du Sud] ; Victor Legrand [Belgique] ; Franz-Josef Neumann [Allemagne] ; Maria Nyakern [Belgique] ; Christian Spaulding [France] ; Hans-Peter Stoll [Belgique] ; Stephen Worthley [Australie] ; Philip Urban [Suisse] | Drug eluting stent implantation in patients requiring concomitant vitamin K antagonist therapy. One-year outcome of the worldwide e-SELECT registry |
| 001376 |
Trevor R. Norman [Australie] ; Ingrid Cranston [Australie] ; Jeremy A. Irons [Australie] ; Cecilia Gabriel [France] ; Anne Dekeyne [France] ; Mark J. Millan [France] ; Elisabeth Mocaer [France] | Agomelatine suppresses locomotor hyperactivity in olfactory bulbectomised rats: A comparison to melatonin and to the 5-HT2c antagonist, S32006 |
| 001709 |
Robert J. Norman [Australie] ; Fernando Zegers-Hochschild [Chili] ; Bruno S. Salle [France] ; Jolanda Elbers [Pays-Bas] ; Esther Heijnen [Pays-Bas] ; Maya Marintcheva-Petrova [Pays-Bas] ; Bernadette Mannaerts [Pays-Bas] | Repeated ovarian stimulation with corifollitropin alfa in patients in a GnRH antagonist protocol: no concern for immunogenicity |
| 001D07 |
Richard C. Becker [États-Unis] ; Jean Pierre Bassand [France] ; Andrzej Budaj [Pologne] ; Daniel M. Wojdyla [États-Unis] ; Stefan K. James [Suède] ; Jan H. Corner [Pays-Bas] ; John French [Australie] ; Claes Held [Suède] ; Jay Horrow [États-Unis] ; Steen Husted [Danemark] ; Jose Lopez-Sendon [Espagne] ; Riitta Lassila [Finlande] ; Kenneth W. Mahaffey [États-Unis] ; Robert F. Storey [Royaume-Uni] ; Robert A. Harrington [États-Unis] ; Lars Wallentin [Suède] | Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial |
| 002301 |
Christian W. Gruber [Autriche] ; Markus Muttenthaler [Australie] ; Michael Freissmuth [Autriche] | Ligand-Based Peptide Design and Combinatorial Peptide Libraries to Target G Protein-Coupled Receptors |
| 002459 |
Florence Wong [Canada] ; Pere Gines [Espagne] ; Hugh Watson [France] ; Yves Horsmans [Belgique] ; Paolo Angeli [Italie] ; Paul Gow [Australie] ; Pascal Minini [France] ; Mauro Bernardi [Italie] | Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis |
| 002560 |
P. Gines [Espagne] ; F. Wong [Canada] ; H. Watson [France] ; R. Terg [Argentine] ; R. Bruha [République tchèque] ; J.-P. Zarski [France] ; F. Dudley [Australie] | Clinical trial: short-term effects of combination of satavaptan, a selective vasopressin V2 receptor antagonist, and diuretics on ascites in patients with cirrhosis without hyponatraemia - a randomized, double-blind, placebo-controlled study |
| 003763 |
Timothy I. Webb [Australie] ; Joseph W. Lynch [Australie] | Molecular pharmacology of the glycine receptor chloride channel |
| 003821 |
David Brieger [Australie] ; Frans Van De Werf [Belgique] ; Alvaro Avezum [Brésil] ; Gilles Montalescot [France] ; Brian M. Kennelly [États-Unis] ; Christopher B. Granger [États-Unis] ; Shaun G. Goodman [Canada] ; Omar H. Dabbous [États-Unis] ; Giancarlo Agnelli [Italie] | Interactions between heparins, glycoprotein llb/llla antagonists, and coronary intervention. The Global Registry of Acute Coronary Events (GRACE) |
| 003903 |
A. J. Lawrence [Australie] ; R. Depoortere [Australie] ; A. L. Auclair [Australie] ; L. Bardin [Australie] ; L. Bruins Slot [Australie] ; M. S. Kleven [Australie, France] ; F. Colpaert [France] ; B. Vacher [France] ; A. Newman-Tancredi [Australie] | F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (III) activity in models of cognition and negative symptoms |
| 003904 |
A. J. Lawrence [Australie] ; R. Depoortere [Australie] ; L. Bardin [Australie] ; A. L. Auclair [Australie] ; M. S. Kleven [Australie, France] ; E. Prinssen [Australie] ; F. Colpaert [France] ; B. Vacher [France] ; A. Newman-Tancredi [Australie] | F15063, a compound with D2/D3 antagonist, 5-HT1A agonist and D4 partial agonist properties: (II) activity in models of positive symptoms of schizophrenia |
| 004970 |
G. Roger [France] ; F. Dolle [France] ; B. De Bruin [France] ; X. Liu [Australie] ; L. Besret [France] ; Y. Bramoulle [France] ; C. Coulon [France] ; M. Ottaviani [France] ; M. Bottlaender [France] ; H. Valette [France] ; M. Kassiou [Australie] | Radiosynthesis and pharmacological evaluation of [11C]EMD-95885: a high affinity ligand for NR2B-containing NMDA receptors |
| 004971 |
Frédéric Dolle [France] ; Héric Valette [France] ; Stéphane Demphel [France] ; Christine Coulon [France] ; Michelle Ottaviani [France] ; Michel Bottlaender [France] ; Michael Kassiou [Australie] | Radiosynthesis and in vivo evaluation of [11C]Ro-647312: a novel NR1/2B subtype selective NMDA receptor radioligand |
| 004C08 |
F. Haab [France] ; L. Stewart [Royaume-Uni] ; P. Dwyer [Australie] ; Linda Cardozo | Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Commentary |
| 004D88 |
Gaëlle Roger [France] ; Béatrice Lagnel [France] ; Laurent Besret [France] ; Yann Bramoulle [France] ; Christine Coulon [France] ; Michelle Ottaviani [France] ; Michael Kassiou [Australie] ; Michel Bottlaender [France] ; Heric Valette [France] ; Frédéric Dolle [France] | Synthesis, radiosynthesis and in vivo evaluation of 5-[3-(4-benzylpiperidin-1-yl)prop-1-ynyl]-1,3-dihydrobenzoimidazol-2-[11C]one, as a potent NR1A/2B subtype selective NMDA PET radiotracer |
| 004F19 |
Christopher G. Sobey [Australie] ; Li Ding-Zhou [France] ; Isabelle Margaill [France] ; Bruno Palmier [France] ; Didier Pruneau [France] ; Michel Plotkine [France] ; Catherine Marchand-Verrecchia [France] | LF 16-0687 MS, a bradykinin B2 receptor antagonist, reduces ischemic brain injury in a murine model of transient focal cerebral ischemia. Commentary |
| 005153 |
Frédéric Bernard [France, Australie] ; Caroline Thomas ; Jean Francois Emile ; Timothy Hercus ; Bruno Cassinat ; Christine Chomienne ; Jean Donadieu | Transient hematologic and clinical effect of E21R in a child with end-stage juvenile myelomonocytic leukemia |
| 005520 |
Lewis J. Rubin [États-Unis] ; David B. Badesch [États-Unis] ; Robyn J. Barst [États-Unis] ; Nazzareno Galie [Italie] ; Carol M. Black [Royaume-Uni] ; Anne Keogh [Australie] ; Tomas Pulido [Mexique] ; Adaani Frost [États-Unis] ; Sébastien Roux [Suisse] ; Isabelle Leconte [Suisse] ; Michael Landzberg [États-Unis] ; Gérald Simonneau [France] | Bosentan therapy for pulmonary arterial hypertension |
| 005833 |
Roland G. Asmar [France] ; Gérard M. London [France] ; Michael E. O'Rourke [Australie] ; Michel E. Safar [France] | Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient: A comparison with atenolol |
| 005931 |
G. Alex [Australie] ; W. A. A. Kunze [Australie] ; J. B. Furness [Australie] ; N. Clerc [France] | Comparison of the effects of neurokinin-3 receptor blockade on two forms of slow synaptic transmission in myenteric AH neurons |
| 005940 |
Ph. Verin [France] ; D. L. Easty [Royaume-Uni] ; A. Secchi [Italie] ; G. Ciprandi [Italie] ; P. Partouche ; G. Nemeth-Wasmer ; R. Brancato [Italie] ; C. J. Harrisberg ; C. Estivin-Ebrardt ; D. J. Coster [Australie] ; A. J. G. Apel [Australie] ; M. T. Coroneo [Australie] ; M. Knorr [Allemagne] ; T. R. Carmichael ; B. T. Kent-Smith [Afrique du Sud] ; P. Abrantes [Portugal] ; A. Leonardi ; P. M. Cerqueti [Italie] ; G. Modorati [Italie] ; M. Martinez [États-Unis] | Clinical evaluation of twice-daily Emedastine 0.05% eye drops (emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis |
| 005993 |
R. Rezaie [France] ; B. Joseph [France] ; J. B. Bremner [Australie] ; P. Delagrange [France] ; C. Kopp [France] ; R. Misslin [France] ; B. Pfeiffer [France] ; P. Renard [France] ; G. Guillaumet [France] | 5-substituted 3,4-dihydro-3-amino-2H-1-benzopyran derivatives: synthesis and interaction with serotoninergic receptors |
| 005C54 |
Pascal Bousquet [France] ; Monique Dontenwill [France] ; Hugues Greney [France] ; Josiane Feldman [France] | Imidazoline receptors in cardiovascular and metabolic diseases |
| 005C67 |
K. R. Lees [Royaume-Uni] ; K. Asplund [Suède] ; A. Carolei [Italie] ; S. M. Davis [Australie] ; H.-C. Diener [Allemagne] ; M. Kaste [Finlande] ; J.-M. Orgogozo [France] ; J. Whitehead [Royaume-Uni] | Glycine antagonist (gavestinel) in neuroprotection (gain international) in patients with acute stroke : A randomised controlled trial |
| 005D23 |
E. J. Topol [États-Unis] ; J. D. Easton [États-Unis] ; P. Amarenco [France] ; R. Califf [États-Unis] ; R. Harrington [États-Unis] ; C. Graffagnino [États-Unis] ; S. Davis [Australie] ; H. C. Diener [Allemagne] ; J. Ferguson [États-Unis] ; D. Fitzgerald [Irlande (pays)] ; A. Shuaib [Canada] ; P. J. Koudstaal [Pays-Bas] ; P. Theroux [Canada] ; F. Van De Werf [Belgique] ; J. T. Willerson [États-Unis] ; R. Chan [États-Unis] ; R. Samuels [États-Unis] ; B. Ilson [États-Unis] ; J. Granett [États-Unis] | Design of the blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion (BRAVO) trial |
| 006294 |
F. J. Mercier [France] ; D. Benhamou [France] | Promising non-narcotic analgesic techniques for labour |
| 006407 |
J. Ong [Australie] ; D. I. B. Kerr [Australie] ; M. Ansar [France] ; C. Vaccher [France] ; P. Berthelot [France] | GABAB receptor antagonism by 7-MBFG, a benzo[b]furan analogue of baclofen, in central and peripheral tissues |
| 006943 |
D. I. B. Kerr [Australie] ; J. Ong [Australie] ; C. Vaccher [France] ; P. Berthelot [France] ; N. Flouquet [France] ; M.-P. Vaccher [France] ; M. Debaert [France] | GABAB receptor antagonism by resolved (R)-saclofen in the guinea-pig ileum |
| 006973 |
M. J. Mckinley [Australie] ; M. L. Mathai [Australie] | Centrally administered losartan inhibits the reduction in plasma renin concentration caused by intracerebroventricular hypertonic saline in Na-depleted sheep |
| 006994 |
I. Olver [Australie] ; W. Paska [Royaume-Uni] ; A. Depierre [France] ; J.-F. Seitz [France] ; D. J. Stewart [Canada] ; L. Goedhals [Afrique du Sud] ; B. Mcquade [Royaume-Uni] ; J. Mcrae [Royaume-Uni] ; J. R. Wilkinson [Royaume-Uni] | A multicentre, double-blind study comparing placebo, ondansetron and ordansetron plus dexamethasone for the control of cisplatin-induced delayed emesis |
| 006A33 |
M. Kassiou [Australie] ; C. Loc'H [France] ; V. Strijckmans [France] ; A. Katsifis [Australie] ; R. M. Lambrecht [Australie] ; M. Maziere [France] ; B. Maziere [France] | Synthesis of [76Br]4-bromolevetimide : radiotracers for studying muscarinic cholinergic receptors using PET |
| 006D11 |
H. R. Brunner [Suisse] ; J. Nussberger ; M. Burnier ; B. Waeber | Angiotensin II antagonists |
